Retirement Systems of Alabama increased its stake in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 0.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,280 shares of the life sciences company’s stock after purchasing an additional 194 shares during the quarter. Retirement Systems of Alabama owned 0.11% of Integra Lifesciences worth $5,154,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IART. Quadrant Capital Group LLC grew its stake in Integra Lifesciences by 223.0% during the 1st quarter. Quadrant Capital Group LLC now owns 646 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 446 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in Integra Lifesciences by 120.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,320 shares of the life sciences company’s stock worth $129,000 after purchasing an additional 1,266 shares in the last quarter. World Asset Management Inc acquired a new position in Integra Lifesciences during the 1st quarter worth $217,000. Stanley Laman Group Ltd. acquired a new position in Integra Lifesciences during the 1st quarter worth $223,000. Finally, Zions Bancorporation N.A. acquired a new position in Integra Lifesciences during the 1st quarter worth $229,000. 82.18% of the stock is owned by hedge funds and other institutional investors.

In other news, COO Glenn Coleman sold 3,500 shares of the business’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $57.50, for a total value of $201,250.00. Following the completion of the sale, the chief operating officer now directly owns 35,194 shares of the company’s stock, valued at approximately $2,023,655. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel L. Reuvers sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the sale, the vice president now directly owns 35,392 shares of the company’s stock, valued at $2,123,520. The disclosure for this sale can be found here. Insiders sold a total of 27,808 shares of company stock valued at $1,509,326 over the last three months. Company insiders own 4.50% of the company’s stock.

Shares of Integra Lifesciences stock traded up $0.64 on Tuesday, hitting $64.15. The stock had a trading volume of 90,206 shares, compared to its average volume of 405,574. Integra Lifesciences Holdings Corp has a 52-week low of $42.14 and a 52-week high of $66.41. The company has a current ratio of 2.76, a quick ratio of 1.82 and a debt-to-equity ratio of 0.99. The firm has a market cap of $5.41 billion, a PE ratio of 26.51, a price-to-earnings-growth ratio of 1.98 and a beta of 1.07. The business has a 50 day moving average price of $54.72.

Integra Lifesciences (NASDAQ:IART) last posted its earnings results on Wednesday, July 24th. The life sciences company reported $0.73 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.08. Integra Lifesciences had a return on equity of 16.30% and a net margin of 6.76%. The business had revenue of $383.60 million during the quarter, compared to the consensus estimate of $373.29 million. During the same period in the previous year, the business earned $0.60 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. As a group, research analysts predict that Integra Lifesciences Holdings Corp will post 2.73 EPS for the current fiscal year.

IART has been the subject of several analyst reports. BidaskClub cut Woodward, Inc.Common Stock from a “strong-buy” rating to a “buy” rating in a research report on Saturday. BTIG Research reaffirmed a “hold” rating on shares of Varian Medical Systems in a research report on Wednesday, July 24th. Royal Bank of Canada set a $179.00 price objective on 3M and gave the stock a “hold” rating in a research report on Friday. Zacks Investment Research raised Hanmi Financial from a “sell” rating to a “hold” rating in a research report on Thursday, June 20th. Finally, JMP Securities upped their price objective on Facebook from $220.00 to $250.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the stock. Integra Lifesciences has an average rating of “Hold” and an average price target of $61.92.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: How do CD ladders protect against rising interest rates?

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).

Institutional Ownership by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.